Michelle Suter, a 63-year-old retiree residing in a St. Louis suburb, has undergone a striking transformation after shedding about 28 pounds with the help of the GLP-1 drug Wegovy. For years, Suter favored loose-fitting attire, convinced she’d never return to her previous sizes after giving away her favorite sundresses. However, her weight loss journey has ignited excitement for a fresh wardrobe. “That’s part of the excitement — to wear things that are new and fit rather than old clothes that you can tie the drawstring tighter,” she said.
Suter, who is halfway to her goal of losing 60 pounds, has already purchased smaller T-shirts and a pair of Hoka sneakers, enabling her to take longer walks with her dogs, Odie and Bentley. Her experience reflects a growing trend among Americans as more individuals turn to weight-loss and diabetes medications. Retailers might find a lucrative opportunity in catering to consumers eager to refresh their closets.
Market research firm Circana reports a decline in larger bra sizes, a significant indicator of changing consumer demand expected to ripple through other clothing categories. Personal styling service Stitch Fix has noted an uptick in customers citing weight loss as a reason for shopping. As barriers to accessing GLP-1 medications diminish-now available in pill form and at reduced prices-more individuals are expected to embrace these treatments. Eli Lilly’s recent launch of the GLP-1 pill Foundayo, along with Novo Nordisk’s Wegovy pill, has resulted in over 600,000 prescriptions within just a few months.
Currently, nearly 13% of U.S. adults are using a GLP-1 drug, with predictions indicating this number could surge to more than 30 million by 2030. Analysts anticipate that as these medications become increasingly accessible, there will be a corresponding spike in apparel demand. Aneesha Sherman, a lead analyst at Bernstein, noted, “There is going to be a tailwind to apparel spending in the U.S. as a result of the uptake of these drugs.”
According to a January survey by Circana, about 80% of GLP-1 users expect to purchase new clothing due to size changes. Many have already begun updating their wardrobes, prompting forecasts that suggest an additional $13 billion could be spent annually on apparel as users transition into smaller sizes.
The shake-up in sizing is particularly evident in the intimate apparel sector, where demand for larger sizes is waning. Victoria’s Secret CEO Hillary Super reported a 3% decline in the sales of bigger sizes, attributing this change to the impact of GLP-1 medications. Analysts predict that this trend will extend to various apparel categories, as shoppers increasingly seek to reflect their changing bodies.
Retailers that could benefit from this trend include off-price retailers like T.J. Maxx and athletic brands like Nike and Lululemon. Stitch Fix is capitalizing on this opportunity by targeting users of weight-loss drugs with specific marketing campaigns and a dedicated landing page on their website. As customers experience rapid changes in body size, they will likely look for stylish options suited for their transformed figures.
In a shifting retail landscape where budget-conscious consumers are prioritizing value, GLP-1 users may find themselves in a prime position to invest in new clothing. “As people are experiencing a rapid physical transformation, they need support,” said Stitch Fix CEO Matt Baer, highlighting the emotional and practical considerations in this buying journey.
As more individuals embark on their weight loss journeys with GLP-1 medications, retailers are poised to see a potential surge in consumer demand for smaller sizes. With changes in personal health leading to shifts in personal style, the fashion industry is preparing for a transformative moment.
—
Tags: GLP-1 drugs, Wegovy, fashion retail, weight loss, apparel trends, consumer behavior, Stitch Fix, health and wellness.
Original Source: https://www.cnbc.com/2026/04/09/weight-loss-pills-glp-1s-stitch-fix-apparel-retailers.html
Category :
Tags:
Publish Date: 2026-04-09 16:30:00
